低アルブミン血症患者におけるテイコプラニンの総最低濃度および有害作用
Hirofumi Oishi1, Yoshimichi Koutake2, Narumi Ebata1
1Department of Pharmacy, NHO Kyushu Medical Center, 1-8-1 Jigyouhama, Chuo-ku, Fukuoka 810-8563, Japan.
まとめ
低アルバミンの患者では,Teicoplanin (TEIC) の低濃度 (Cmin) が21. 1μg/ mlを超える場合,肝臓損傷のリスクが増加する可能性があります. TEICの安全性に関するこれらの発見を確認するには,さらなる研究が必要である.
科学分野:
- 薬理学について
- 臨床薬局
- 内科 医学
背景:
- テイコプラニン (TEIC) の最低濃度 (Cmin) と肝毒性,腎毒性,血小板減少などの有害事象の関係については,十分に確立されていません.
- 低血清アルブミンの状態である低アルブミニアは,薬物の分泌と排出に影響を与え,薬物の安全性プロフィールを潜在的に変化させる可能性があります.
研究 の 目的:
- TEIC Cminと肝毒性,腎毒性,および血小板減少症の発生との関連を調査する.
- この脆弱な患者集団におけるTEIC誘発の有害事象に寄与する特定の危険因子を特定する.
主な方法:
- TEICを投与された成人患者で,血清アルブミン濃度<2. 5g/ dLの持続性のある研究が行われました.
- 治療薬のモニタリングを行い,TEIC Cminと有害事象の関係を評価するために多変量ロジスティック回帰分析を使用した.
主要な成果:
- 肝毒性,腎毒性,および血小板減少は,それぞれ13. 5%,19. 0%および14. 4%の患者で発生しました.
- TEIC Cmin ≥21. 1μg/ mL,血清アルブミン<2. 0g/ dL,全腸内栄養は肝毒性に関連していた.
- 肝臓毒性に関連する要因には,肝炎/肝硬変および血管圧縮剤の使用が含まれています. 血小板減少は腎機能障害,血小板数の低下,高尿血症,および血液学的疾患と関連していました.
結論:
- TEIC Cmin ≥21. 1μg/ mLは,ハイポアルブミネミアの患者でテイコプラニン誘発性肝毒性のリスクを高める可能性があります.
- 特定の臨床的要因は,TEIC誘発性腎臓毒性および血小板減少と関連しています.
- これらの発見を検証し,低アルバミネミックな患者におけるTEICの使用に関する臨床ガイドラインを改訂するために,さらなる研究が必要である.
さらに関連する動画
関連する概念動画
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
111
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
111
01:18Factors Affecting Protein-Drug Binding: Drug-Related Factors
188
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
188
01:09Hepatic Drug Clearance: Effect of Protein Binding
284
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
284
01:29Drug Distribution: Plasma Protein Binding
6.6K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
6.6K
01:13Therapeutic Index
5.0K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
5.0K
01:20Factors Affecting Protein-Drug Binding: Protein-Related Factors
249
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
249